The Drug Controller General of India (DCGI) has allowed us to market Durvalumab, a cancer treatment medicine in the country, AstraZenecaPharma India said on Thursday.

In an official statement, the company announced that drug regulator has given its nod to import and market the cancer treatment medicine. After getting green signal from DCGI, now AstraZeneca Pharma will be able to launch the product in the country.

Durvalumab is useful medicine for treating those patients who are suffering from locally advanced, unresectable non-small cell lung Cancer (NSCLC) and metastatic urothelial carcinoma

Responding to the development, Gagan Singh, AstraZeneca Pharma India Managing Director, said:  “The import and market permission for Durvalumab for unresectable stage III Non-Small Cell Lung Cancer (NSCLC) and locally advanced or metastatic urothelial carcinoma is a significant milestone for patients who have currently limited treatment options.”

In India, around one third of patients with NSCLC are present with stage III disease and the company is happy to bring the first immunotherapy into this setting for patients, he added.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.